Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.

British journal of haematology·2022

Same author

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Haematologica·2014

Same author

Chronic myeloid leukemia in India.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology·2014

Same author

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

British journal of haematology·2013

Same author

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

The Journal of clinical investigation·2013

Same author

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Blood·2013

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Treatment strategies for CML.

John M Goldman¹

¹Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, UK. jgoldman@imperial.ac.uk

Best Practice & Research. Clinical Haematology

|December 5, 2009

Summary

This summary is machine-generated.

The introduction of imatinib, a tyrosine kinase inhibitor (TKI), revolutionized chronic myeloid leukemia (CML) treatment. Many patients achieve long-term remission, with some able to discontinue therapy safely.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 18, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Chronic myeloid leukemia (CML) treatment saw limited progress until the 1980s with interferon-alpha and stem cell transplantation.
The development of targeted therapies has significantly improved patient outcomes.

Purpose of the Study:

To review the impact of imatinib, the first BCR-ABL1 specific tyrosine kinase inhibitor (TKI), on CML treatment.
To discuss long-term outcomes and alternative strategies for CML patients.

Main Methods:

Review of clinical data and treatment guidelines for imatinib in CML.
Analysis of long-term response rates and survival data.

Main Results:

Imatinib is the recommended initial treatment for chronic phase (CP) CML.
Approximately two-thirds of patients achieve complete cytogenetic response lasting over 7 years.
A small subset of patients can safely stop imatinib without relapse.
Second-generation TKIs or stem cell transplantation are options for treatment failure.

Conclusions:

Imatinib has fundamentally changed CML management, offering durable responses.
Long-term therapy is effective, and treatment discontinuation is possible for some patients.
Alternative therapies are available for patients who do not respond to imatinib.